Abstract
Human interleukin 5 (IL5) is the major hematopoietin that stimulates the proliferation, migration and activation of eosinophils and is implicated in the pathogenesis of inflammatory and other myeloproliferative diseases. IL5 functions through the signaling of a common receptor subunit β (βc), in a receptor activation process that requires initial recruitment of an IL5 specific receptor subunit α (IL5Rα), for cytokine presentation to βc. Important advances have been made to understand molecular mechanisms of cytokine recognition and receptor antagonism. Mutational studies indicate that a pair of charge complementary regions play an essential role in specific interaction between IL5Rα and IL5. Moreover, peptide studies with the IL5 system have identified a cyclic peptide inhibitor, AF17121, which binds specifically to IL5Rα by mimicking the cytokine. A key receptor-recognition pharmacophore has been identified in this peptide inhibitor, and sites of inhibitor recognition can be proposed in the homology-deduced structural model of IL5Rα. These results provide an experimental platform to derive enhanced-potency peptidomimetic inhibitors. Such inhibitors have potential use as tools to evaluate the role of eosinophilia in disease and as potential leads to antagonists to treat hyper-eosinophilic diseases such as eosinophilic esophagitis, asthma and chronic myeloproliferative leukemias.
Current Pharmaceutical Design
Title: Structure-Based Rationale for Interleukin 5 Receptor Antagonism
Volume: 14 Issue: 12
Author(s): Tetsuya Ishino, Adrian E. Harrington, Hosahudya Gopi and Irwin Chaiken
Affiliation:
Abstract: Human interleukin 5 (IL5) is the major hematopoietin that stimulates the proliferation, migration and activation of eosinophils and is implicated in the pathogenesis of inflammatory and other myeloproliferative diseases. IL5 functions through the signaling of a common receptor subunit β (βc), in a receptor activation process that requires initial recruitment of an IL5 specific receptor subunit α (IL5Rα), for cytokine presentation to βc. Important advances have been made to understand molecular mechanisms of cytokine recognition and receptor antagonism. Mutational studies indicate that a pair of charge complementary regions play an essential role in specific interaction between IL5Rα and IL5. Moreover, peptide studies with the IL5 system have identified a cyclic peptide inhibitor, AF17121, which binds specifically to IL5Rα by mimicking the cytokine. A key receptor-recognition pharmacophore has been identified in this peptide inhibitor, and sites of inhibitor recognition can be proposed in the homology-deduced structural model of IL5Rα. These results provide an experimental platform to derive enhanced-potency peptidomimetic inhibitors. Such inhibitors have potential use as tools to evaluate the role of eosinophilia in disease and as potential leads to antagonists to treat hyper-eosinophilic diseases such as eosinophilic esophagitis, asthma and chronic myeloproliferative leukemias.
Export Options
About this article
Cite this article as:
Ishino Tetsuya, Harrington E. Adrian, Gopi Hosahudya and Chaiken Irwin, Structure-Based Rationale for Interleukin 5 Receptor Antagonism, Current Pharmaceutical Design 2008; 14 (12) . https://dx.doi.org/10.2174/138161208784246144
DOI https://dx.doi.org/10.2174/138161208784246144 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effectiveness of Interventions to Address Health Inequalities During Pregnancy: A Review of Relevant Literature
Current Women`s Health Reviews An Overview of the α4β1 Integrin and the Potential Therapeutic Role of its Antagonists
Current Medicinal Chemistry Anti-Viral
Current Bioactive Compounds Phosphoinositide 3-Kinases and Leukocyte Migration
Current Immunology Reviews (Discontinued) Biological Properties of Citrus Flavonoids Pertaining to Cancer and Inflammation
Current Medicinal Chemistry Synthesis and Evaluation of Morpholinoethyl Ester Conjugate of N-acetylcysteine in Ovalbumin-induced Airway Hyperresponsiveness in Sprague Dawley Rats
Letters in Drug Design & Discovery Editorial: Pharmacotherapy of Alcohol Dependence: Past, Present and Future Research
Current Pharmaceutical Design Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Combination Therapeutic Approach for Asthma and Allergic Rhinitis
Current Clinical Pharmacology Correlations between the Youth Healthy Eating Index, Body Mass Index and the Salivary Nitric Oxide Concentration in Overweight/Obese Children
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug Repositioning: A Unique Approach to Refurbish Drug Discovery
Current Drug Discovery Technologies Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting
Current Molecular Medicine System Level Meta-analysis of Microarray Datasets for Elucidation of Diabetes Mellitus Pathobiology
Current Genomics Antisense Oligonucleotide Drug Design
Current Pharmaceutical Design Echocardiogram versus Cardiac Magnetic Resonance Imaging for the Diagnosis of Non-compaction Cardiomyopathy – A Case Report
New Emirates Medical Journal Gender Disparity in Pediatric Diseases
Current Molecular Medicine Effects Of A Selective Histamine H<sub>4</sub>R Antagonist On Inflammation In A Model Of Carrageenan-Induced Pleurisy In The Rat
Current Pharmaceutical Design Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Current Gene Therapy Prioritizing Disease Genes by Using Search Engine Algorithm
Current Bioinformatics Novel Biological Therapies in Severe Asthma: Targeting the Right Trait
Current Medicinal Chemistry